Search results
Results from the WOW.Com Content Network
1440 12985 Ensembl ENSG00000108342 ENSMUSG00000038067 UniProt P09919 P09920 RefSeq (mRNA) NM_000759 NM_001178147 NM_172219 NM_172220 NM_009971 RefSeq (protein) NP_000750 NP_001171618 NP_757373 NP_757374 NP_034101 Location (UCSC) Chr 17: 40.02 – 40.02 Mb Chr 11: 98.59 – 98.59 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Granulocyte colony-stimulating factor (G-CSF or GCSF ...
Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF). [19] It works by stimulating the body to increase neutrophil production. [19] Filgrastim was approved for medical use in the United States in 1991. [19] It is on the World Health Organization's List of Essential Medicines.
The name "colony-stimulating factors" comes from the method by which they were discovered. Hematopoietic stem cells were cultured (see cell culture) on a so-called semisolid matrix, which prevents cells from moving around, so that, if a single cell starts proliferating, all of the cells derived from it will remain clustered around the spot in the matrix where the first cell was originally located.
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute ...
Sargramostim is a version of GM-CSF, which has a normal role in human biology, causing progenitor cells to differentiate into neutrophils, monocytes, macrophages, and, myeloid-derived dendritic cells; it can also activate mature granulocytes and macrophages, and can contribute to the differentiation of megakaryocytic progenitors and erythroid ...
Some drugs (e.g. otilimab) are being developed to block GM-CSF. [22] In critically ill patients GM-CSF has been trialled as a therapy for the immunosuppression of critical illness, and has shown promise restoring monocyte [23] and neutrophil [24] function, although the impact on patient outcomes is currently unclear and awaits larger studies.
Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales. Abbreviations are used in the list as follows: INN = International Nonproprietary Name
The US Food and Drug Administration (FDA) approved motixafortide based on evidence from the GENESIS study, a double-blind, placebo-controlled study, in which 122 participants with multiple myeloma, due to undergo autologous transplantation, were randomized 2:1 to receive motixafortide 1.25 mg/kg with granulocyte-colony stimulating factor (N=80) or placebo with granulocyte-colony stimulating ...